Pharma's Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post launch. No wonder...

Riding the Wearables Trend: Opportunities for Pharma Wearable health technology is causing a stir in Pharma with benefits across the business from smarter clinical research and improved patient monitoring and adherence...

The Future of Market Access in Europe The challenges and barriers to market access across Europe continue to be widely debated against the ever-present backdrop of cost-cutting and budgetary pressures. At the same time,...

How is brand health being impacted by new RA market entrants? The battle is on. Anti-TNF Biosimilars for rheumatoid arthritis (RA) have arrived in the US and we can now start to see the first changes in perception...

The Future of Biosimilars in the USA Can pharma resolve the litigation frenzy hampering biosimilars' market entry in the US? Is too much focus on legal wrangling stifling healthy competition and innovation? And, as the...

Don’t let good ratings fool you. Your medical affairs teams may still be letting doctors down Our latest survey shows that while US medical affairs teams for growth hormone brands are doing a reasonably good job,...

How well does your CLL medical affairs team performance compare with the rest? Is ‘moderately satisfied’ good enough? According to this latest survey of 100 US medical oncologists and haematologists, the...

Eliminating market barriers could help lower-ranked brands a narrow lead Three brands are way ahead in the US non-small cell lung cancer (NSCLC) market, thanks in part to market barriers that prevent oncologists from...